{
  "id": 16461778,
  "title": "#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity",
  "url": "https://urgent.news/2026/10/25/esmo26-pfizer-looks-beyond-lung-cancer-flop-as-biontech-bristol-myers",
  "topic": "world",
  "section": "World",
  "published": "2026-10-25T10:00:51.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/esmo26-pfizer-says-failed-adc-from-seagen-buy-shows-promise-in-post-hoc-review/"
  },
  "original_language": "en",
  "account": null,
  "summary": "MADRID — Pfizer is moving past its late-stage loss in non-small cell lung cancer, pointing to a post-hoc analysis of earlier-line patients who appear to benefit. Also on Sunday, BioNTech and Bristol Myers Squibb touted ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}